We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+59.12%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$8.26B
AUM Growth
+$2.81B
Cap. Flow
+$660M
Cap. Flow %
7.99%
Top 10 Hldgs %
46.78%
Holding
97
New
16
Increased
23
Reduced
35
Closed
10
Avg Time Held
1.3 years
Top 10 Avg Time Held
1.5 years
Top 20 Avg Time Held
1 year

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$242M
2
STTK icon
Shattuck Labs
STTK
+$181M
3
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
+$164M
4
ABBV icon
AbbVie
ABBV
+$133M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$91.4M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$275M
2
BNTX icon
BioNTech
BNTX
+$64.3M
3
BSX icon
Boston Scientific
BSX
+$54.3M
4
FOLD icon
Amicus Therapeutics
FOLD
+$50.2M
5
AXNX icon
Axonics, Inc. Common Stock
AXNX
+$37.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
2 Technology 0.52%
3 Financials 0.46%
4 Consumer Staples 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AMED icon
51
DELISTED
Amedisys
AMED
$39.2M 0.47%
133,480
-6,700
-5% -$1.72M
2019 Q2
6 quarters
SLQT icon
52
SelectQuote
SLQT
$59M
$38.3M 0.46%
1,844,719
+489,415
+36% +$10M
2020 Q2
2 quarters
QURE icon
53
uniQure
QURE
$1.53B
$37.2M 0.45%
1,028,898
-99,929
-9% -$4.22M
2018 Q2
10 quarters
PRAH
54
DELISTED
PRA Health Sciences, Inc.
PRAH
$33.3M 0.4%
265,736
-12,200
-4% -$1.36M
2019 Q3
5 quarters
CNC icon
55
Centene
CNC
$34.4B
$33.3M 0.4%
+554,962
New +$35.3M
2020 Q4
0 quarters
CTLT icon
56
DELISTED
CATALENT, INC.
CTLT
$32.7M 0.4%
314,519
-14,900
-5% -$1.44M
2020 Q1
3 quarters
RCEL icon
57
Avita Medical
RCEL
$409M
$31.7M 0.38%
1,707,386
-72,200
-4% -$1.58M
2020 Q3
1 quarter
PPD
58
DELISTED
PPD, Inc. Common Stock
PPD
$28.2M 0.34%
823,192
-29,900
-4% -$1.04M
2020 Q1
3 quarters
ARDX icon
59
Ardelyx
ARDX
$808M
$22.7M 0.28%
3,514,100
– –
2019 Q4
4 quarters
IMTX icon
60
Immatics
IMTX
$1.04B
$22.3M 0.27%
2,068,301
-61,699
-3% -$651K
2020 Q3
1 quarter
PAND
61
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$20.8M 0.25%
1,398,705
+279,105
+25% +$3.88M
2020 Q3
1 quarter
HOOK icon
62
DELISTED
HOOKIPA Pharma
HOOK
$20.4M 0.25%
184,290
– –
2019 Q2
6 quarters
ABCL icon
63
AbCellera Biologics
ABCL
$3.86B
$20.1M 0.24%
+500,000
New +$22.9M
2020 Q4
0 quarters
LUNG icon
64
Pulmonx
LUNG
$76.9M
$19M 0.23%
+275,000
New +$13.5M
2020 Q4
0 quarters
CABA icon
65
Cabaletta Bio
CABA
$244M
$17.2M 0.21%
1,378,319
-8,265
-0.6% -$107K
2019 Q4
4 quarters
PROF icon
66
Profound Medical
PROF
$224M
$17M 0.21%
825,197
+197
+0% +$3.62K
2020 Q1
3 quarters
CTSO icon
67
Cytosorbents Corp
CTSO
$11.1M
$16.4M 0.2%
102,707
-2,350
-2% -$393K
2020 Q3
1 quarter
STXS icon
68
Stereotaxis
STXS
$104M
$15.8M 0.19%
3,103,327
– –
2019 Q3
5 quarters
ITMR
69
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$14.1M 0.17%
711,500
+86,500
+14% +$1.73M
2020 Q1
3 quarters
GRTS icon
70
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$12.1M 0.15%
3,059,794
– –
2018 Q3
9 quarters
XERS icon
71
Xeris Biopharma Holdings
XERS
$1.82B
$11.8M 0.14%
2,397,441
– –
2018 Q2
10 quarters
SKIN icon
72
SkinHealth Systems
SKIN
$78.3M
$11.3M 0.14%
+50,000
New +$10.8M
2020 Q4
0 quarters
KA icon
73
DELISTED
Kineta, Inc. Common Stock
KA
$10.4M 0.13%
+87,286
New +$13.3M
2020 Q4
0 quarters
AYLA
74
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$7.61M 0.09%
667,816
+1,150
+0.2% +$13.3K
2020 Q2
2 quarters
SEER icon
75
Seer Inc
SEER
$113M
$7.02M 0.09%
+125,000
New +$7.95M
2020 Q4
0 quarters
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2020 Portfolio in Review

As of Q4 2020, Redmile Group held 97 positions worth $8.26B, up 52% from $5.45B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Redmile Group deployed $660M of net new capital in Q4 2020, opening 16 new positions and adding to 23 existing holdings. Its largest new stake was Shattuck Labs: 5,619,914 shares worth $295M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was BioNTech, an estimated $64.3M trimmed.

  • Redmile Group's largest Q4 2020 buy was Shattuck Labs: 5,619,914 shares worth $295M.
  • Redmile Group added most to Invitae Corporation in Q4 2020, an estimated $242M increase.
  • Redmile Group's biggest Q4 2020 reduction was BioNTech, cutting an estimated $64.3M.
  • Redmile Group fully exited Immunomedics Inc in Q4 2020, selling an estimated $275M.
  • Redmile Group's ten largest holdings make up 47% of its $8.26B portfolio in Q4 2020.
  • Redmile Group opened 16 new positions and closed 10 in Q4 2020.
  • Redmile Group's portfolio value rose 52% quarter-over-quarter to $8.26B.

Based on Redmile Group's 13F filing for Q4 2020, filed 16 Feb 2021.